Family · Pharmaceutical analytical standards
Orlistat
An inhibitor of lipases, the enzymes that digest fat in the gut: it partly blocks fat absorption and is used to treat obesity; it was first marketed in 1998 and approved in the US in 1999. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It derives from lipstatin, described in 1987 in the soil bacterium Streptomyces toxytricini: orlistat is its saturated version, chosen because it is simpler and more stable.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
